Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (MRSN): 9 pipeline candidates · ~54 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
54.3 months
D/E -2.05 · 0% dilution
Lead: Approved
9 candidates
N/A
N/A
A transparent, data-derived signal for Mersana Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$56.9M
Quarterly Burn
$3.2M
Runway
54.3 mo
Revenue
$11.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| abiraterone | Approved |
| bortezomib | Approved |
| clofarabine | Approved |
| emi-le | Phase 1 |
| famotidine | Approved |
| nilotinib | Approved |
| teriflunomide | Approved |
| xmt-1660 | Phase 1 |
| xmt-2056 | Phase 1 |
Frequently asked questions
How many drug candidates are in Mersana Therapeutics, Inc.'s pipeline?
Mersana Therapeutics, Inc. (MRSN) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mersana Therapeutics, Inc.'s lead drug candidate?
Mersana Therapeutics, Inc.'s most advanced tracked candidate is abiraterone (Approved) for 1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablet is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC). (1) Metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 ).
What is Mersana Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mersana Therapeutics, Inc. has approximately 54.3 months of cash runway.
Who is the CEO of Mersana Therapeutics, Inc.?
Martin Huber, M.D. is the chief executive officer of Mersana Therapeutics, Inc. (MRSN).
Get the full picture on Mersana Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.